Posted by Michael Wonder on 29 Aug 2024
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalised myasthenia gravis
29 August 2024 - Filing based on the Phase 3 Vivacity-MG3 program, the first-and-only study results in the class demonstrating sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+.
Johnson & Johnson today announced the submission of a biologics license application to the US FDA seeking the first approval of nipocalimab globally for the treatment of people living with generalised myasthenia gravis.
